Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Date: Sunday, November 13, 2022

Time: 9:00AM-10:30AM

Meeting: ACR Convergence 2022

9:00AM-10:30AM: Abstract Number: 0812

3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) – Data from the RELIANCE Registry

9:00AM-10:30AM: Abstract Number: 0829

Adult Onset Still’s Disease: A Retrospective Study of Objective Manifestations and Outcomes

9:00AM-10:30AM: Abstract Number: 0810

Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis

9:00AM-10:30AM: Abstract Number: 0832

Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflammatory Conditions?

9:00AM-10:30AM: Abstract Number: 0813

Canakinumab in Patients with Tumor Necrosis Factor Receptor-associated Periodic Syndrome (TRAPS) – Long-term Efficacy and Safety Data from a RELIANCE Registry Interim Analysis

9:00AM-10:30AM: Abstract Number: 0814

Clinical Correlation of Dense Fine Speckled (DFS) Pattern of ANA

9:00AM-10:30AM: Abstract Number: 0819

Connective Tissue Disease-Related Interstitial Lung Disease: Trends from an Urban Academic Tertiary Care Center

9:00AM-10:30AM: Abstract Number: 0809

Ex Vivo Comparative Immunogenicity Assessment (EVCIA) to Determine Relative Immunogenicity in Chronic Plaque Psoriasis in Participants Receiving Humira® or Undergoing Repeated Switches Between Humira and AVT02

9:00AM-10:30AM: Abstract Number: 0807

High Throughput Analyses for the Study of Synovial Tissue Biopsy from Inflammatory Arthritis Patients

9:00AM-10:30AM: Abstract Number: 0815

Hyper-IgG4 in Patients with Systemic Autoinflammatory Disease

9:00AM-10:30AM: Abstract Number: 0821

Imiquimod Exaggerates Obesity-associated Adipose Tissue Inflammation in Murine Psoriasis Model

9:00AM-10:30AM: Abstract Number: 0828

Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease

9:00AM-10:30AM: Abstract Number: 0816

Increased Risk of Hepatotoxicity with DMARDS in Patients with Previous Liver Toxicity with Isoniazid: Study in a Single University Hospital

9:00AM-10:30AM: Abstract Number: 0824

Lessons Learned from a Cohort of Adult Afro-Caribbean Patients Diagnosed Clinically with Dermatomyositis

9:00AM-10:30AM: Abstract Number: 0830

Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis

9:00AM-10:30AM: Abstract Number: 0831

Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital

9:00AM-10:30AM: Abstract Number: 0818

NLRP12-associated Autoinflammatory Disease in Chinese Adult Patients: A Single-center Study

9:00AM-10:30AM: Abstract Number: 0822

Optimal Use of Colchicine in COVID-19 Management from Rheumatologists’ Perspective: A Monocentric Observational Study During the SARS-CoV-2 Delta Variant Pandemic

9:00AM-10:30AM: Abstract Number: 0825

Predicting Outcomes in Macrophage Activation Syndrome (MAS): A Retrospective Study on 43 Consecutive Patients with MAS

9:00AM-10:30AM: Abstract Number: 0817

Predictive Severity Factors of COVID-19 in Patients with Rheumatic Immune Mediated Diseases

9:00AM-10:30AM: Abstract Number: 0823

Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome: A Systematic Literature Review

9:00AM-10:30AM: Abstract Number: 0811

Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction

9:00AM-10:30AM: Abstract Number: 0820

Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study

9:00AM-10:30AM: Abstract Number: 0808

Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital

9:00AM-10:30AM: Abstract Number: 0826

Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Treatment in Patients with Adult Still’s Disease: An Analysis of a Japanese Claims Database

9:00AM-10:30AM: Abstract Number: 0827

Unpublished Clinical Trials of Major Rheumatic Diseases

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].